Sat.Jul 29, 2023 - Fri.Aug 04, 2023

article thumbnail

Waters Launches SEC Columns for Gene Therapy Applications

PharmaTech

Waters XBridge Premier GTx BEH size exclusion chromatography (SEC) columns are designed to improve analysis while lowering the cost of gene therapies.

97
article thumbnail

Intas analyst poured acid over manufacturing docs, FDA says in scathing warning letter

Fierce Pharma

Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. | The FDA handed Intas a five-observation write up after inspecting the company’s Sanand, India, production plant from November 22 to December 2, 2022. The company got dinged for lapses in quality control, incomplete lab records, testing shortfalls and more.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How My Brother’s Death Changed The Way I Think About Mental Health Care

MedCity News

As clinical psychologists, we talk about therapy as the gold standard. I’m not saying it isn’t, but if only a minority of people are getting it, we need to broaden our perspective.

article thumbnail

New HIV drug formulation could transform paediatric administration

European Pharmaceutical Review

A new study published in The Lancet HIV has demonstrated the safety and efficacy of a new dispersible drug formulation of an immediate-release tablet as a human immunodeficiency virus (HIV) treatment for children. The single fixed dose combination (FDC) contains dolutegravir , abacavir and lamivudine. “This is the first FDC containing dolutegravir that can be used for children from 13 to 88 pounds,” explained Kristina Brooks, PharmD, an Assistant Professor in the University of Colorado Skaggs Sc

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Solving time crunch and profile challenges for researchers

Clarivate

How librarians can relieve administrative burdens and drive researcher effectiveness In today’s fast-paced world of research, time has become an increasingly scarce and valuable resource. An independent study commissioned by Ex Libris revealed that “academic researchers face a significant challenge in finding enough time to effectively manage their research activities.

article thumbnail

As COVID revenues disappoint, once-high-flying Pfizer looks at possible cost cuts

Fierce Pharma

As COVID-19 revenues ebb and flow—but mostly ebb—Pfizer is eyeing the cost-cutting shears. | Paxlovid generated just $143 million in worldwide sales for the second quarter, while mRNA vaccine Comirnaty brought home $1.4 billion. Against that backdrop, Pfizer reported total second quarter revenues of $12.7 billion, down a whopping 53% operationally from the same period last year.

Sales 246

More Trending

article thumbnail

New European monograph for Cannabis flower adopted

European Pharmaceutical Review

The Danish Medicines Agency (Lægemiddelstyrelsen) has announced the European Pharmacopoeia Commission has adopted a new European monograph, which describes quality requirements for the raw material Cannabis flower. EPC’s new Cannabis flower monograph The new monograph Cannabis flower (Cannabis flower, monograph 3028) will be available next year in January 2024 with publication of the supplement 11.5.

Medical 98
article thumbnail

Attracting Young Talent in Pharma

PharmExec

Rebekah Martin, senior VP of reward, inclusion, and talent acquisition at AstraZeneca, discusses ways to address the need for talent in pharma, how pharma can increase more interest in young talent, and how many roles in pharma will require a degree in the coming years in this Pharmaceutical Executive Podcast video.

Pharma 98
article thumbnail

As sales crater, Moderna sees hope in private COVID vaccine market and RSV launch

Fierce Pharma

Even as Moderna chugs through another post-pandemic year, the biotech has raised its COVID-19 vaccine revenue projection in the expectation that it can deliver a strong showing in the private marke | The company raised its forecast for COVID-19 sales to between $6 billion and $8 billion, up from a prior estimate of $5 billion. Elsewhere, an RSV clash with pharma giants nears.

Sales 246
article thumbnail

Navigating research challenges through collaboration and Equity

Clarivate

Trends point to growing interest by major funding organizations in international collaborative research. Understanding the funding landscape can make bid success more likely. Scientific research is increasingly collaborative. The once siloed approach to research activity has given way to a more interconnected global model, which has enabled a global research network to evolve.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

MHRA authorises new COVID-19 vaccine

European Pharmaceutical Review

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. MHRA authorisation of Bimervax The COVID-19 vaccine, developed by HIPRA Human Health, combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, according to the MHRA.

article thumbnail

Driving for Results: 3 Key Benefits of Telehealth [Sponsored]

MedCity News

Explore the myriad benefits telehealth offers to healthcare providers and patients alike. From enhanced convenience and improved privacy to streamlined workflows and elevated patient satisfaction, find out how telehealth is reshaping the future of healthcare delivery.

article thumbnail

GSK beats Merck to first PD-1 approval in newly diagnosed endometrial cancer

Fierce Pharma

GSK has won the first FDA approval for an immunotherapy to treat certain patients with newly diagnosed endometrial cancer. But the industry-first go-ahead is tempered with a label limitation. | GSK has won the first FDA approval for an immunotherapy to treat certain patients with newly diagnosed endometrial cancer. But the industry-first go-ahead is tempered with a label limitation.

FDA 246
article thumbnail

AstraZeneca and Pfizer Ink $1 Billion Rare Disease Deal

PharmaTech

AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Accelerating biomanufacturing with automated PAT systems

European Pharmaceutical Review

Research published in Biotechnology and Bioengineering has demonstrated two innovative, automatic, online, real-time sample acquisition and preparation systems for in-process monitoring, control, and release of biopharmaceuticals. The proposed autonomous process analytical technology (PAT) platform comprises of a micro sequential injection (µSI) process analyser and automatic assay preparation platform (A2P2) for use in the laboratory as an off-line analytical system and on the manufacturing flo

article thumbnail

Labor Department Sues UnitedHealth Group Over ‘Thousands’ of Claims Denials

MedCity News

The Labor Department recently sued UnitedHealth Group subsidiary UMR, alleging that it wrongfully denied claims for emergency room services and urinary drug screenings since 2015. UMR did not determine the medical necessity of the claims, denying them “based solely on diagnosis codes and not applying a prudent layperson standard,” according to the complaint.

Medical 97
article thumbnail

Novo Nordisk, Eli Lilly face injury lawsuit from user of popular GLP-1 medicines

Fierce Pharma

As Novo Nordisk and Eli Lilly rack up significant sales from their GLP-1 diabetes and obesity drugs, the companies also must gear up for defense against lawsuits from new users. | A Louisiana woman is suing Novo Nordisk and Eli Lilly, alleging that her use of Ozempic and Mounjaro caused her to vomit so much that some of her teeth have fallen out. Jaclyn Bjorklund, 44, says that she also has been hospitalized on "several" occasions and that the companies failed to warn patients of “seve

Medicine 246
article thumbnail

Visually Guided Uterine Biopsies in Physician’s Office: Interview with Allison London Brown, CEO of LUMINELLE

Medgadget

LUMINELLE , a medtech company based in North Carolina, has developed a suite of endoscopic tools that allow clinicians to perform visually guided gynecological procedures right from their office. At present, the majority of uterine biopsies taken to investigate the cause of abnormal uterine bleeding are taken blind, with no visual guidance at all. This leads to suboptimal outcomes, and the frequent need to repeat the biopsy procedure because the first attempt did not yield an adequate sample.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

New immuno-oncology treatment approved for endometrial cancer

European Pharmaceutical Review

The only immuno- oncology treatment approved as frontline therapy for mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), primary advanced or recurrent endometrial cancer in combination with chemotherapy, is now authorised in the US. Jemperli (dostarlimab), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the US Food and Drug Administration (FDA).

article thumbnail

What We Can Learn From Health Systems Around the World

MedCity News

I am a practicing UK general practitioner and in this article, I take a magnifying glass to quality indicators including access, affordability, healthcare inequalities and population health, staffing and equipment, and patient and provider experience to discuss how we can shape up.

article thumbnail

Bristol Myers, AstraZeneca settle PD-1, CTLA-4 cancer immunotherapy patent suits for $510M

Fierce Pharma

Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster cancer immunotherapies. | Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster PD-1/L1 and CTLA-4 cancer immunotherapies.

246
246
article thumbnail

Pharma Marketing in the Age of AI: A New Era Begins

PharmExec

This podcast companion to our roundtable feature explores the transformative power of AI in pharmaceutical marketing, six months after the arrival of ChatGPT.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Innovation passport designation awarded to Pfizer and Arvinas

European Pharmaceutical Review

Arvinas, Inc. and Pfizer Inc. have been awarded an Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ® ER degrader, as a treatment for oestrogen receptor (ER)+/ human epidermal growth factor receptor (HER)2- locally-advanced breast cancer or metastatic breast cancer. The award was jointly granted by the UK Innovative Licensing and Access Pathway Steering Group, which consists of the All Wales Therapeutics and Toxicology Centre (AWTTC), the Medicines and Healthcare produc

article thumbnail

Average Healthcare Data Breach Cost Reaches Nearly $11M

MedCity News

The average cost of a healthcare data breach is now $10.93 million, up from $10.10 million in 2022, according to a new report. Healthcare has the highest data breach costs of all industries — breaches are second costliest in the financial sector, where the average cost is $5.9 million.

article thumbnail

Johnson & Johnson's $8.9B talc deal in jeopardy as judge shoots down 2nd bankruptcy attempt

Fierce Pharma

Johnson & Johnson’s attempt to end its talc litigation with a sweeping $8.9 billion settlement didn’t pass muster at the bankruptcy court, which instead dismissed the company's latest bankruptc | U.S. Bankruptcy Judge Michael Kaplan ruled that J&J's LTL Management subsidiary didn't establish immediate financial distress when it applied for bankruptcy protections.

article thumbnail

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

PharmaVoice

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

CDKL5 deficiency-associated seizure treatment approved in EU

European Pharmaceutical Review

The first treatment for children and adolescents who have epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) has been approved in the EU by the European Commission (EC). EC has granted approval of ZTALMY ® (ganaxolone) oral suspension as adjunctive treatment in CDD patients from two to 17 years old. The European regulatory body’s decision “represents a significant milestone” according to Dr Scott Braunstein, Chairman and Chief Executive Off

article thumbnail

‘We Can Be More Selective About Who We Treat’: UHS CFO’s Comments Spark Concerns About Cherry-Picking

MedCity News

Last week, the CFO of Universal Health Services stated that the company chooses which patients to treat based on whose insurance plans offer the highest payments. The comments have sparked some media attention, but healthcare finance experts say the practice of cherry-picking patients is nothing new to the industry.

article thumbnail

Takeda's Exkivity sputters in lung cancer trial, with accelerated approval on the line

Fierce Pharma

An accelerated approval for a potential growth driver for Takeda is in danger. | Takeda's targeted non-small cell lung med Exkivity has failed in a phase 3 trial in newly diagnosed patients, just days after Johnson & Johnson touted a win for its rival EGFR inhibitor.

Patients 246
article thumbnail

Bangladesh and the dengue vaccine question

Pharmaceutical Technology

Amid one of the worst dengue fever outbreaks in decades, Bangladesh has recorded the highest number of hospitalised cases of the disease in a day.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time